ASX - By Stock
|
PER |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
Baremoney
|
45 |
12K |
4 |
17/10/23 |
17/10/23 |
ASX - By Stock
|
45
|
12K
|
4
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
Baremoney
|
190 |
53K |
19 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
190
|
53K
|
19
|
|
ASX - By Stock
|
PER |
Re:
Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial
|
|
Baremoney
|
34 |
13K |
13 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
34
|
13K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial
|
|
Baremoney
|
34 |
13K |
7 |
08/06/23 |
08/06/23 |
ASX - By Stock
|
34
|
13K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Chief Executive Officer and Managing Director Appointment
|
|
Baremoney
|
107 |
29K |
4 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
107
|
29K
|
4
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
Baremoney
|
1.0K |
317K |
10 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
1.0K
|
317K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing
|
|
Baremoney
|
31 |
10K |
15 |
26/04/23 |
26/04/23 |
ASX - By Stock
|
31
|
10K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Fresh Start
|
|
Baremoney
|
105 |
30K |
1 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
105
|
30K
|
1
|
|
ASX - By Stock
|
PER |
Re:
ANP Value
|
|
Baremoney
|
328 |
94K |
0 |
25/10/22 |
25/10/22 |
ASX - By Stock
|
328
|
94K
|
0
|
|
ASX - By Stock
|
PER |
Re:
ANP Value
|
|
Baremoney
|
328 |
94K |
2 |
25/10/22 |
25/10/22 |
ASX - By Stock
|
328
|
94K
|
2
|
|
ASX - By Stock
|
PER |
Re:
ANP Value
|
|
Baremoney
|
328 |
94K |
6 |
25/10/22 |
25/10/22 |
ASX - By Stock
|
328
|
94K
|
6
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Baremoney
|
3.5K |
1.0M |
0 |
28/09/22 |
28/09/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: ATL1102 Revised Plans accelerate reporting of unblinded data
|
|
Baremoney
|
351 |
90K |
2 |
07/09/22 |
07/09/22 |
ASX - By Stock
|
351
|
90K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long Covid-19 Collaboration Outcomes Presentation
|
|
Baremoney
|
228 |
88K |
2 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
228
|
88K
|
2
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
12 |
19/08/22 |
19/08/22 |
Charts
|
5.9K
|
2.3M
|
12
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long Covid-19 Collaboration Outcomes Presentation
|
|
Baremoney
|
228 |
88K |
14 |
19/08/22 |
19/08/22 |
ASX - By Stock
|
228
|
88K
|
14
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
Baremoney
|
168 |
65K |
22 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
168
|
65K
|
22
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
Baremoney
|
168 |
65K |
9 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
168
|
65K
|
9
|
|
ASX - By Stock
|
TPD |
Re:
Ann: Results of the Share Purchase Plan
|
|
Baremoney
|
43 |
17K |
0 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
43
|
17K
|
0
|
|
ASX - By Stock
|
TPD |
Re:
Ann: STX: Walyering Flow Test Materially Exceeds Expectations
|
|
Baremoney
|
121 |
49K |
8 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
121
|
49K
|
8
|
|
ASX - By Stock
|
TPD |
Re:
Ann: STX: Walyering Flow Test Materially Exceeds Expectations
|
|
Baremoney
|
121 |
49K |
0 |
06/05/22 |
06/05/22 |
ASX - By Stock
|
121
|
49K
|
0
|
|
ASX - By Stock
|
TPD |
Re:
Ann: STX: Walyering Flow Test Materially Exceeds Expectations
|
|
Baremoney
|
121 |
49K |
11 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
121
|
49K
|
11
|
|
ASX - By Stock
|
TPD |
Re:
Ann: STX: Walyering Flow Test Materially Exceeds Expectations
|
|
Baremoney
|
121 |
49K |
13 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
121
|
49K
|
13
|
|
ASX - By Stock
|
PER |
Re:
CR Shortfall
|
|
Baremoney
|
99 |
30K |
1 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
99
|
30K
|
1
|
|
ASX - By Stock
|
PER |
Re:
CR Shortfall
|
|
Baremoney
|
99 |
30K |
1 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
99
|
30K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Poster Presentation at 2022 MDA Conference
|
|
Baremoney
|
67 |
22K |
7 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
67
|
22K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long COVID-19 strategic collaboration with US Experts
|
|
Baremoney
|
245 |
72K |
1 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
245
|
72K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Long COVID-19 strategic collaboration with US Experts
|
|
Baremoney
|
245 |
72K |
4 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
245
|
72K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present at XIX International Conference on DMD
|
|
Baremoney
|
24 |
7.5K |
3 |
21/02/22 |
21/02/22 |
ASX - By Stock
|
24
|
7.5K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP to present at XIX International Conference on DMD
|
|
Baremoney
|
24 |
7.5K |
5 |
17/02/22 |
17/02/22 |
ASX - By Stock
|
24
|
7.5K
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
1 |
09/11/21 |
09/11/21 |
Charts
|
5.9K
|
2.3M
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
5 |
09/11/21 |
09/11/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
Charts
|
PER |
Re:
Chart
|
|
Baremoney
|
5.9K |
2.3M |
5 |
09/11/21 |
09/11/21 |
Charts
|
5.9K
|
2.3M
|
5
|
|
ASX - By Stock
|
PER |
Re:
See How Wee Go
|
|
Baremoney
|
62 |
18K |
13 |
08/11/21 |
08/11/21 |
ASX - By Stock
|
62
|
18K
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ann: Prospectus
|
|
Baremoney
|
79 |
21K |
3 |
07/11/21 |
07/11/21 |
ASX - By Stock
|
79
|
21K
|
3
|
|
ASX - By Stock
|
PER |
Re:
$36.8m raise
|
|
Baremoney
|
219 |
72K |
5 |
06/11/21 |
06/11/21 |
ASX - By Stock
|
219
|
72K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive PDCO opinion and A$20m Placement
|
|
Baremoney
|
166 |
51K |
2 |
05/11/21 |
05/11/21 |
ASX - By Stock
|
166
|
51K
|
2
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Baremoney
|
855 |
245K |
18 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
855
|
245K
|
18
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive PDCO opinion and A$20m Placement
|
|
Baremoney
|
166 |
51K |
5 |
02/11/21 |
02/11/21 |
ASX - By Stock
|
166
|
51K
|
5
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Baremoney
|
855 |
245K |
1 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
855
|
245K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive PDCO opinion and A$20m Placement
|
|
Baremoney
|
166 |
51K |
1 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
166
|
51K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive PDCO opinion and A$20m Placement
|
|
Baremoney
|
166 |
51K |
11 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
166
|
51K
|
11
|
|
ASX - By Stock
|
PER |
Re:
$36.8m raise
|
|
Baremoney
|
219 |
72K |
4 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
219
|
72K
|
4
|
|
ASX - By Stock
|
PER |
Re:
$36.8m raise
|
|
Baremoney
|
219 |
72K |
2 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
219
|
72K
|
2
|
|
ASX - By Stock
|
PER |
Re:
$36.8m raise
|
|
Baremoney
|
219 |
72K |
7 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
219
|
72K
|
7
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Baremoney
|
855 |
245K |
5 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
855
|
245K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
Baremoney
|
143 |
51K |
35 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
143
|
51K
|
35
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
Baremoney
|
143 |
51K |
11 |
28/10/21 |
28/10/21 |
ASX - By Stock
|
143
|
51K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Where others have failed will Atl1102 succeed ?
|
|
Baremoney
|
1.0K |
374K |
10 |
26/10/21 |
26/10/21 |
ASX - By Stock
|
1.0K
|
374K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Baremoney
|
221 |
82K |
6 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
221
|
82K
|
6
|
|